|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Tonn JC and Brada M: High-grade
malignant glioma: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 21(Suppl 5): v190–v193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sathornsumetee S, Reardon DA, Desjardins
A, Quinn JA, Vredenburgh JJ and Rich JN: Molecularly targeted
therapy for malignant glioma. Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen Z, Zhai XF, Su YH, Wan XY, Li J, Xie
JM and Gao B: Clinical observation of cinobufacini injection used
to treat moderate and advanced primary liver cancer. Zhong Xi Yi
Jie He Xue Bao. 1:184–186. 2003.In Chinese. View Article : Google Scholar
|
|
7
|
Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP
and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined
with huachansu in patients with advanced gallbladder carcinoma.
World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge
Y, Newman RA, Cohen L, Liu L, Thornton B, et al: Pilot study of
huachansu in patients with hepatocellular carcinoma, nonsmall-cell
lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan B, He J, Kisoh K, Hayashi H, Tanaka
S, Si N, Zhao HY, Hirano T, Bian B and Takagi N: Effects of active
bufadienolide compounds on human cancer cells and
CD4+CD25+Foxp3+ regulatory T cells
in mitogen-activated human peripheral blood mononuclear cells.
Oncol Rep. 36:1377–1384. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Facciabene A, Motz GT and Coukos G:
T-regulatory cells: Key players in tumor immune escape and
angiogenesis. Cancer Res. 72:2162–2171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maruyama T, Kono K, Mizukami Y, Kawaguchi
Y, Mimura K, Watanabe M, Izawa S and Fujii H: Distribution of Th17
cells and FoxP3(+) regulatory T cells in tumor-infiltrating
lymphocytes, tumor-draining lymph nodes and peripheral blood
lymphocytes in patients with gastric cancer. Cancer Sci.
101:1947–1954. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sakaguchi S: Naturally arising
Foxp3-expressing CD25+CD4+ regulatory T cells
in immunological tolerance to self and non-self. Nat Immunol.
6:345–352. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kon A, Yuan B, Hanazawa T, Kikuchi H, Sato
M, Furutani R, Takagi N and Toyoda H: Contribution of membrane
progesterone receptor α to the induction of progesterone-mediated
apoptosis associated with mitochondrial membrane disruption and
caspase cascade activation in Jurkat cell lines. Oncol Rep.
30:1965–1970. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao M, Yuan B, Wang X, Sato A, Sakuma K,
Kaneko K, Komuro H, Okazaki A, Hayashi H, Toyoda H, et al:
Synergistic cytotoxic effects of arsenite and tetrandrine in human
breast cancer cell line MCF-7. Int J Oncol. 51:587–598. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan B, Okusumi S, Yoshino Y, Moriyama C,
Tanaka S, Hirano T, Takagi N and Toyoda H: Delphinidin induces
cyto-toxicity and potentiates cytocidal effect in combination with
arsenite in an acute promyelocytic leukemia NB4 cell line. Oncol
Rep. 34:431–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng LJ, Hu LP, Peng QL, Yang XL, Bai LL,
Yiu A, Li Y, Tian HY, Ye WC and Zhang DM: Hellebrigenin induces
cell cycle arrest and apoptosis in human hepatocellular carcinoma
HepG2 cells through inhibition of Akt. Chem Biol Interact.
219:184–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng LJ, Peng QL, Wang LH, Xu J, Liu JS,
Li YJ, Zhuo ZJ, Bai LL, Hu LP, Chen WM, et al: Arenobufagin
intercalates with DNA leading to G2 cell cycle arrest via ATM/ATR
pathway. Oncotarget. 6:34258–34275. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu CM, Tsai Y, Wan L and Tsai FJ: Bufalin
induces G2/M phase arrest and triggers autophagy via the TNF, JNK,
BECN-1 and ATG8 pathway in human hepatoma cells. Int J Oncol.
43:338–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chakravarti A, Zhai GG, Zhang M, Malhotra
R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J:
Survivin enhances radiation resistance in primary human
glioblastoma cells via caspase-independent mechanisms. Oncogene.
23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kikuchi H, Yuan B, Yuhara E, Takagi N and
Toyoda H: Involvement of histone H3 phosphorylation through p38
MAPK pathway activation in casticin-induced cytocidal effects
against the human promyelocytic cell line HL-60. Int J Oncol.
43:2046–2056. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao J, Qian CJ, Ye B, Zhang X and Liang Y:
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis
via NF-κB-dependent and Notch-independent mechanism. Life Sci.
91:186–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kikuchi H, Yuan B, Yuhara E, Imai M,
Furutani R, Fukushima S, Hazama S, Hirobe C, Ohyama K, Takagi N, et
al: Involvement of histone H3 phosphorylation via the activation of
p38 MAPK pathway and intracellular redox status in cytotoxicity of
HL-60 cells induced by Vitex agnus-castus fruit extract. Int J
Oncol. 45:843–852. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zanotto-Filho A, Braganhol E, Battastini
AM and Moreira JC: Proteasome inhibitor MG132 induces selective
apoptosis in glioblastoma cells through inhibition of PI3K/Akt and
NFkappaB pathways, mitochondrial dysfunction, and activation of
p38-JNK1/2 signaling. Invest New Drugs. 30:2252–2262. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Phong MS, Van Horn RD, Li S,
Tucker-Kellogg G, Surana U and Ye XS: p38 mitogen-activated protein
kinase promotes cell survival in response to DNA damage but is not
required for the G(2) DNA damage checkpoint in human cancer cells.
Mol Cell Biol. 30:3816–3826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pereira L, Igea A, Canovas B, Dolado I and
Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to
cisplatin-induced apoptosis mediated by reactive oxygen species and
JNK. EMBO Mol Med. 5:1759–1774. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sooman L, Lennartsson J, Gullbo J,
Bergqvist M, Tsakonas G, Johansson F, Edqvist PH, Pontén F, Jaiswal
A, Navani S, et al: Vandetanib combined with a p38 MAPK inhibitor
synergistically reduces glioblastoma cell survival. Med Oncol.
30:6382013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Heerden FR and Vleggaar R: A revised
13C NMR spectral assignment of hellebrigenin. Magn Reson Chem.
26:464–467. 1988. View Article : Google Scholar
|
|
29
|
Hayashi H, Campenot RB, Vance DE and Vance
JE: Glial lipo-proteins stimulate axon growth of central nervous
system neurons in compartmented cultures. J Biol Chem.
279:14009–14015. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cao YD, Zhang LZ, Wang MS, Tang TY and Su
WH: Two methods to collect cerebrospinal fluid in SD rat. Acta Acad
Med XuZhou. 25:317–319. 2005.
|
|
31
|
Yoshino Y, Yuan B, Kaise T, Takeichi M,
Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of
aquaporin 9 and multidrug resistance-associated protein 2 to
differential sensitivity to arsenite between primary cultured
chorion and amnion cells prepared from human fetal membranes.
Toxicol Appl Pharmacol. 257:198–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuan B, Ohyama K, Bessho T, Uchide N and
Toyoda H: Imbalance between ROS production and elimination results
in apoptosis induction in primary smooth chorion trophoblast cells
prepared from human fetal membrane tissues. Life Sci. 82:623–630.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cesarone CF, Bolognesi C and Santi L:
Improved microfluorometric DNA determination in biological material
using 33258 Hoechst. Anal Biochem. 100:188–197. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kreuter J: Nanoparticulate systems for
brain delivery of drugs. Adv Drug Deliv Rev. 47:65–81. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li F, Weng Y, Wang L, He H, Yang J and
Tang X: The efficacy and safety of bufadienolides-loaded
nanostructured lipid carriers. Int J Pharm. 393:203–211. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu CL and Hou HM: Plasma pharmacokinetics
and tissue distribution of bufotalin in mice following single-bolus
injection and constant-rate infusion of bufotalin solution. Eur J
Drug Metab Pharmacokinet. 35:115–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gavet O and Pines J: Progressive
activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell.
18:533–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perdiguero E and Nebreda AR: Regulation of
Cdc25C activity during the meiotic G2/M transition. Cell Cycle.
3:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao S, Tsuchida T, Kawakami K, Shi C and
Kawamoto K: Effect of As2O3 on cell cycle progression and cyclins
D1 and B1 expression in two glioblastoma cell lines differing in
p53 status. Int J Oncol. 21:49–55. 2002.PubMed/NCBI
|
|
40
|
Momeny M, Moghaddaskho F, Gortany NK,
Yousefi H, Sabourinejad Z, Zarrinrad G, Mirshahvaladi S, Eyvani H,
Barghi F, Ahmadinia L, et al: Blockade of vascular endothelial
growth factor receptors by tivozanib has potential anti-tumour
effects on human glioblastoma cells. Sci Rep. 7:440752017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang YX, Li XF, Yuan GQ, Hu H, Song XY,
Li JY, Miao XK, Zhou TX, Yang WL, Zhang XW, et al: β-Arrestin 1 has
an essential role in neurokinin-1 receptor-mediated glioblastoma
cell proliferation and G2/M phase transition. J Biol Chem.
292:8933–8947. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic
Strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shirai K, Suzuki Y, Oka K, Noda SE, Katoh
H, Suzuki Y, Itoh J, Itoh H, Ishiuchi S, Sakurai H, et al: Nuclear
survivin expression predicts poorer prognosis in glioblastoma. J
Neurooncol. 91:353–358. 2009. View Article : Google Scholar
|
|
44
|
Li Y, Liu D, Zhou Y, Li Y, Xie J, Lee RJ,
Cai Y and Teng L: Silencing of survivin expression leads to reduced
proliferation and cell cycle arrest in cancer cells. J Cancer.
6:1187–1194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A,
Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, et al: Arenobufagin,
a natural bufadienolide from toad venom, induces apoptosis and
autophagy in human hepatocellular carcinoma cells through
inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis. 34:1331–1342.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gutiérrez-Uzquiza Á, Arechederra M,
Bragado P, Aguirre-Ghiso JA and Porras A: p38α mediates cell
survival in response to oxidative stress via induction of
antioxidant genes: Effect on the p70S6K pathway. J Biol Chem.
287:2632–2642. 2012. View Article : Google Scholar
|
|
49
|
Chen Y, Yang W, Zhang X, Yang S, Peng G,
Wu T, Zhou Y, Huang C, Reinach PS, Li W, et al: MK2 inhibitor
reduces alkali burn-induced inflammation in rat cornea. Sci Rep.
6:281452016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yoshino Y, Aoyagi M, Tamaki M, Duan L,
Morimoto T and Ohno K: Activation of p38 MAPK and/or JNK
contributes to increased levels of VEGF secretion in human
malignant glioma cells. Int J Oncol. 29:981–987. 2006.PubMed/NCBI
|
|
51
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Marampon F, Megiorni F, Camero S,
Crescioli C, McDowell HP, Sferra R, Vetuschi A, Pompili S, Ventura
L, De Felice F, et al: HDAC4 and HDAC6 sustain DNA double strand
break repair and stem-like phenotype by promoting radioresistance
in glioblastoma cells. Cancer Lett. 397:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fine HA, Dear KB, Loeffler JS, Black PM
and Canellos GP: Meta-analysis of radiation therapy with and
without adjuvant chemotherapy for malignant gliomas in adults.
Cancer. 71:2585–2597. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Stewart LA: Chemotherapy in adult
high-grade glioma: A systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet.
359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
